je.st
news
Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA (pembrolizumab) in Lung Cancer and Melanoma
2015-03-31 14:00:00| Merck.com - Product News
Dateline City: WALTHAM, Mass. & KENILWORTH, N.J. WALTHAM, Mass. & KENILWORTH, N.J.--(BUSINESS WIRE)--Syndax Pharmaceuticals, Inc., and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that they have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Syndaxs entinostat, an investigational epigenetic therapy, with Mercks KEYTRUDA (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orMerck Investor Relations:Justin Holko, 908-740-1879orSyndax Corporate:Bob Goodenow, 781-419-1418Chief Business Officerbgoodenow@syndax.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
combination
cancer
evaluating
Category:Biotechnology and Pharmaceuticals